Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334685 | 0.83 | CYP1A2 (0.33) | HTR2AHTR2CHTR2BCASP3 | |
| SCHEMBL31553097 | 0.81 | HTR2A (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL17843510 | 0.81 | CYP1A2 (0.39) | — | |
| SCHEMBL23218588 | 0.74 | ALOX15 (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL16844564 | 0.74 | HTR2A (0.35) | HTR2AHTR2CHTR2B | |
| SCHEMBL789665 | 0.74 | HTR2A (0.32) | HTR2AHTR2CHTR2B | |
| SCHEMBL6948759 | 0.74 | RARA (0.33) | — | |
| SCHEMBL19776376 | 0.74 | CYP3A4 (0.39) | — | |
| SCHEMBL23363949 | 0.74 | — | — | |
| SCHEMBL6952377 | 0.74 | HTR2A (0.33) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435054-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2025-05-29 | — | — | US | disclosed |
| US-12275745-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2025-04-15 | — | — | US | disclosed |
| WO-2025021148-A1 | WRN INHIBITOR, AND PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 贝达药业股份有限公司 | 2025-01-30 | — | — | WO | disclosed |
| EP-4185386-B1 | HETEROCYCLIC INHIBITORS OF TEAD FOR TREATING CANCER | GENENTECH INC (US) | 2025-01-08 | — | — | EP | disclosed |
| EP-4436969-A2 | BICYCLIC THERAPEUTIC COMPOUNDS AND METHODS OF USE IN THE TREATMENT OF CANCER | Genentech, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| CN-118451077-A | Bicyclic therapeutic compounds and methods for treatment of cancer | 基因泰克公司 | 2024-08-06 | — | — | CN | disclosed |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| US-11787775-B2 | Therapeutic compounds and methods of use | GENENTECH, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| CN-100542534-C | Substituted piperazines | CHEMOCENTRYX INC (US) | 2009-09-23 | — | — | CN | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589199-B2 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| EP-1691810-A4 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX INC (US) | 2009-07-01 | — | — | EP | disclosed |
| EP-1691810-A1 | SUBSTITUTED PIPERAZINES | ChemoCentryx Inc (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060106218-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2006-05-18 | — | — | US | disclosed |
| US-20050256130-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2005-11-17 | — | — | US | disclosed |
| WO-2005056015-A1 | SUBSTITUTED PIPERAZINES | CHEMOCENTRYX, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171464-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, TP53, MCL1 | AHR 1684/4885HTR2A 3460/4885HTR2C 2898/4885 |
| US-20240208919-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | VHL, NQO1, PCSK9 | AHR 1181/4885HTR2A 3742/4885HTR2C 3397/4885 |
| US-11787775-B2 | Therapeutic compounds and methods of use | VHL, NQO1, PCSK9 | AHR 1181/4885HTR2A 3742/4885HTR2C 3397/4885 |
| US-20060106218-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | AHR 84/4885HTR2A 588/4885HTR2C 547/4885 |
| US-12435054-B2 | Therapeutic compounds and methods of use | VHL, NQO1, PCSK9 | AHR 1181/4885HTR2A 3742/4885HTR2C 3397/4885 |
| US-20050256130-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | AHR 84/4885HTR2A 588/4885HTR2C 547/4885 |
| US-12275745-B2 | Therapeutic compounds and methods of use | VHL, TP53, MCL1 | AHR 1684/4885HTR2A 3460/4885HTR2C 2898/4885 |
| US-20100240618-A1 | SUBSTITUTED PIPERAZINES | CCR1, CCR3, CCRL2 | AHR 84/4885HTR2A 588/4885HTR2C 547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.